Arrowhead Pharmaceuticals
Price & Volume
Stats
See moreOpen | $18.21 |
Previous Close | $18.28 |
Day Range | $18.21-$18.82 |
52W Range | $17.05-$39.83 |
Market Cap | $2.2B |
Shares Short | 9M |
Financials
See moreRevenue (12 Mos) | $19.6M |
Revenue Growth (YoY) | -94.3% |
Gross Profit (12 Mos) | $240.7M |
Diluted EPS | -$4.65 |
News
See moreYahoo Finance • 2 months ago
With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners
Yahoo Finance • 3 months ago
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Yahoo Finance • 4 months ago
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
Yahoo Finance • 5 months ago
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
About
CEO | Dr. Christopher R. Anzalone Ph.D. |
Address | 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 525 |
